CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma: Overall, the treatment was well tolerated in mice, and co-targeting PD-L1, AK, and PI3K may represent a reasonable and novel strategy for the treatment of PTCL (Islam et al., 2017).